Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

NCT04362137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

432

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytokine Storm (Covid-19)

Interventions

DRUG: Ruxolitinib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]